Global CAR T-Cell Therapy Market

1. Summary

The Global CAR T-Cell Therapy Market was valued at $8.5 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 28.5% CAGR, to an estimated market size of $29.8 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.

2. Market Definition

The market for CAR T-cell therapy involves the development and commercialization of immunotherapies where a patient's T-cells are genetically engineered to express chimeric antigen receptors to target specific cancer antigens. It primarily includes treatments for hematologic malignancies like leukemia and lymphoma, while excluding traditional chemotherapy and non-engineered cell therapies.

3. Trends & Demand Drivers

Several key trends are expected to significantly impact the CAR T-Cell Therapy Market in the period 2025-30:

• The market is witnessing a strategic shift from last-resort treatments to earlier-line therapies to improve patient outcomes and survival rates.
• Significant R&D is focused on expanding applications from blood cancers to solid tumors such as breast, lung, and gastric cancers.
• The development of allogeneic (off-the-shelf) platforms aims to overcome the scalability and high cost limitations of patient-specific autologous treatments.
• Advancements in automated manufacturing and closed-loop systems are reducing the critical vein-to-vein turnaround time for patients.
• Integration of CRISPR-based gene editing and AI is enhancing the precision, safety, and efficacy of next-generation CAR constructs.
• High treatment costs and complex reimbursement landscapes remain significant barriers to widespread global adoption and patient access.

4. Market Breakdown

The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments: